Insider Selling: Medpace Holdings, Inc. (NASDAQ:MEDP) CEO Sells $6,051,220.38 in Stock

Medpace Holdings, Inc. (NASDAQ:MEDP) CEO August J. Troendle sold 15,102 shares of the firm’s stock in a transaction that occurred on Monday, April 29th. The stock was sold at an average price of $400.69, for a total transaction of $6,051,220.38. Following the sale, the chief executive officer now owns 791,541 shares in the company, valued at $317,162,563.29. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Medpace Trading Up 0.4 %

Shares of MEDP opened at $392.57 on Friday. The company has a market cap of $12.16 billion, a price-to-earnings ratio of 40.02, a PEG ratio of 1.98 and a beta of 1.40. Medpace Holdings, Inc. has a 1-year low of $197.39 and a 1-year high of $421.00. The company’s fifty day simple moving average is $398.08 and its 200 day simple moving average is $330.45.

Medpace (NASDAQ:MEDP) last issued its earnings results on Monday, April 22nd. The company reported $3.20 earnings per share for the quarter, topping analysts’ consensus estimates of $2.45 by $0.75. The business had revenue of $511.00 million for the quarter, compared to the consensus estimate of $512.39 million. Medpace had a net margin of 15.92% and a return on equity of 59.74%. The firm’s revenue for the quarter was up 17.7% on a year-over-year basis. During the same period in the previous year, the company earned $2.27 earnings per share. As a group, research analysts forecast that Medpace Holdings, Inc. will post 11.23 earnings per share for the current year.

Hedge Funds Weigh In On Medpace

A number of institutional investors have recently added to or reduced their stakes in MEDP. Wellington Management Group LLP increased its holdings in Medpace by 312.6% during the third quarter. Wellington Management Group LLP now owns 421,313 shares of the company’s stock worth $102,013,000 after buying an additional 319,210 shares during the last quarter. TD Asset Management Inc raised its position in shares of Medpace by 195.2% in the fourth quarter. TD Asset Management Inc now owns 467,041 shares of the company’s stock valued at $143,162,000 after purchasing an additional 308,816 shares during the period. Invesco Ltd. raised its position in shares of Medpace by 67.6% in the third quarter. Invesco Ltd. now owns 611,900 shares of the company’s stock valued at $148,159,000 after purchasing an additional 246,775 shares during the period. Findlay Park Partners LLP bought a new stake in shares of Medpace during the 1st quarter worth about $90,247,000. Finally, Norges Bank bought a new stake in shares of Medpace during the 4th quarter worth about $59,163,000. 77.98% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several analysts have commented on MEDP shares. Robert W. Baird raised their target price on shares of Medpace from $446.00 to $454.00 and gave the stock an “outperform” rating in a report on Wednesday, April 24th. Jefferies Financial Group upgraded shares of Medpace from a “hold” rating to a “buy” rating and lifted their price objective for the company from $340.00 to $450.00 in a report on Tuesday, April 23rd. Guggenheim lifted their price objective on shares of Medpace from $453.00 to $464.00 and gave the company a “buy” rating in a report on Wednesday, April 24th. Deutsche Bank Aktiengesellschaft assumed coverage on shares of Medpace in a report on Monday, March 18th. They issued a “hold” rating and a $395.00 price objective on the stock. Finally, StockNews.com upgraded shares of Medpace from a “hold” rating to a “buy” rating in a report on Tuesday, April 23rd. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $443.00.

Medpace Company Profile

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.